| |
| |
| Exchange: |
Nasdaq Small Cap |
| Security
Type: |
Common |
| Shares
Out: |
151,572,000 |
| Market
Cap: |
8.34(B) |
| Last
Volume: |
501,923 |
Avg
Vol: |
500,553 |
| 52
Week Range: |
$19.24 - $56.98 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Insmed is a biopharmaceutical company. Co.'s commercial product, ARIKAYCE, is approved in the U.S. for the treatment of Mycobacterium avium complex lung disease and in Europe for the treatment of nontuberculous mycobacterial lung infections. Co.'s pipelines include: brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis, cystic fibrosis and other neutrophil-mediated diseases; and treprostinil palmitil inhalation powder, an inhaled formulation of the treprostinil prodrug treprostinil palmitil for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
95,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$1,709,450 |
| Total People Bought |
0 |
0 |
0 |
2 |
| Total Buy Transactions |
0 |
0 |
0 |
5 |
| Total Shares Sold |
525,422 |
694,534 |
825,123 |
1,226,977 |
| Total Sell Value |
$24,358,586 |
$29,388,785 |
$32,444,566 |
$42,349,832 |
| Total People Sold |
7 |
7 |
7 |
7 |
| Total Sell Transactions |
16 |
37 |
41 |
74 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Farrar Doug |
Vice President, ITP |
• – – |
2007-12-31 |
5 |
B |
$0.69 |
$10,624 |
D/D |
15,420 |
29,309 |
|
- |
|
| Engelsen Steinar J |
Director |
– • – |
2007-11-14 |
4 |
B |
$0.97 |
$51,300 |
D/D |
50,000 |
98,125 |
2.39 |
- |
|
| Farrar Doug |
Vice President, ITP |
• – – |
2007-06-30 |
5 |
B |
$0.69 |
$9,570 |
D/D |
13,889 |
13,889 |
|
- |
|
| Crooke Graham K |
Director |
– • – |
2007-06-27 |
4 |
B |
$0.84 |
$8,360 |
D/D |
10,000 |
60,000 |
2.39 |
- |
|
| Tully Kevin P |
Executive VP & CFO |
• – – |
2007-06-27 |
4 |
B |
$0.79 |
$34,199 |
D/D |
43,300 |
142,252 |
2.74 |
- |
|
| Glover Steve C |
President Follow-on Biologics |
• – – |
2007-06-25 |
4 |
B |
$0.78 |
$62,936 |
D/D |
80,000 |
80,000 |
2.74 |
- |
|
| Allan Geoffrey |
President, CEO and Chairman |
• • – |
2007-06-21 |
4 |
B |
$0.72 |
$117,975 |
D/D |
165,000 |
1,166,464 |
2.81 |
- |
|
| Tully Kevin P |
Executive VP and CFOOfficer |
• – – |
2006-02-20 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
98,952 |
|
- |
|
| Condon Kenneth G |
officerTitle |
– • – |
2005-12-16 |
4 |
S |
$1.80 |
$5,540 |
D/D |
(3,078) |
100 |
|
- |
|
| Condon Kenneth G |
officerTitle |
– • – |
2005-12-16 |
4 |
S |
$1.80 |
$16,240 |
I/I |
(9,000) |
450,513 |
|
- |
|
| Condon Kenneth G |
officerTitle |
– • – |
2005-12-15 |
4 |
S |
$1.80 |
$1,593 |
D/D |
(885) |
3,178 |
|
- |
|
| Condon Kenneth G |
officerTitle |
– • – |
2005-12-15 |
4 |
S |
$1.80 |
$1,260 |
I/I |
(700) |
459,513 |
|
- |
|
| Gunn Ronald D |
Executive Vice President & COO |
• – – |
2005-01-11 |
4 |
OE |
$0.92 |
$5,496 |
D/D |
6,000 |
40,074 |
|
- |
|
| Allan Geoffrey |
President, CEO and Chairman |
• • – |
2005-01-01 |
4 |
OE |
$0.91 |
$80,001 |
D/D |
87,500 |
1,001,464 |
|
- |
|
| Crooke Graham K |
Director |
– • – |
2004-11-30 |
4 |
B |
$1.59 |
$7,979 |
D/D |
5,000 |
50,000 |
2.39 |
- |
|
| Crooke Graham K |
Director |
– • – |
2004-08-04 |
4 |
B |
$1.43 |
$7,299 |
D/D |
5,000 |
45,000 |
2.39 |
- |
|
| Sommer Andreas |
Chief Scientific OfficerOffice |
• – – |
2004-03-04 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
6,601 |
|
- |
|
| Condon Kenneth G |
Director |
– • – |
2004-01-05 |
4 |
S |
$3.11 |
$52,924 |
I/I |
(17,000) |
460,213 |
|
- |
|
| Condon Kenneth G |
Director |
– • – |
2004-01-02 |
4 |
S |
$3.01 |
$12,056 |
I/I |
(4,000) |
477,213 |
|
- |
|
| Condon Kenneth G |
Director |
– • – |
2003-12-31 |
4 |
S |
$3.00 |
$600 |
I/I |
(200) |
481,213 |
|
- |
|
| Condon Kenneth G |
Director |
– • – |
2003-12-29 |
4 |
S |
$3.00 |
$17,401 |
I/I |
(5,800) |
481,413 |
|
- |
|
| Condon Kenneth G |
Director |
– • – |
2003-12-26 |
4 |
S |
$3.00 |
$24,000 |
I/I |
(8,000) |
487,213 |
|
- |
|
| Gunn Ronald D |
Executive Vice President |
• – – |
2003-12-23 |
4 |
OE |
$0.57 |
$6,517 |
D/D |
7,183 |
34,074 |
|
- |
|
| Condon Kenneth G |
Director |
– • – |
2003-12-15 |
4 |
S |
$3.00 |
$6,000 |
I/I |
(2,000) |
495,213 |
|
- |
|
| Condon Kenneth G |
Director |
– • – |
2003-10-17 |
4 |
S |
$3.36 |
$336 |
I/I |
(100) |
497,213 |
|
- |
|
584 Records found
|
|
Page 23 of 24 |
|
|
1.93 (3.39%) 
